Robert Azelby, MBA

Prior to joining Alder BioPharmaceuticals, Mr. Azelby was Juno Therapeutics’ Executive Vice President, Chief Commercial Officer reporting to the CEO where he was a standing member of Juno’s Executive Team participating in the management of all aspects of Juno’s operations and was personally accountable for leading and developing Juno’s commercial capabilities. In addition to the commercial function, Mr. Azelby oversaw and lead the development of Juno’s project management, corporate affairs and medical science liaison functions. Before Juno, Mr. Azelby was the Vice President and General Manager of Amgen’s US Oncology Business Unit representing $6.5 Billion. Over his 15 year career with Amgen, Mr. Azelby held numerous sales and marketing positions including Vice President U.S. Oncology Sales, Vice President of North American Commercial Operations, General Manager, Amgen Netherlands, Senior Marketing Director, etc. Prior to Amgen, Mr. Azelby was Chief Operating Officer for a venture-capital-backed early-stage company specializing in catastrophic event medical management. Mr. Azelby also held the position of Chief Financial Officer for a subsidiary of Oxford Health Plans and was also a Professional Sales Representative for GlaxoWellcome. Mr. Azelby received his undergraduate degrees in Economics and Religious Studies from the University of Virginia and his Master of Business Administration from Harvard University.

Paul Carter

Mr. Carter has served as a member of our board of directors since September 2015. Since April 2006, Mr. Carter has served in various roles at Gilead Sciences, Inc., a research-based biopharmaceutical company, and currently serves as Gilead’s Executive Vice President, Commercial Operations. Prior to joining Gilead, he spent 14 years in the pharmaceutical industry with GlaxoSmithKline and its legacy companies. During his time with GlaxoSmithKline, Mr. Carter gained increasing levels of senior experience as General Manager in Europe and later as a Regional Head of the International business in Asia. Mr. Carter holds a degree in Business Studies from the Ealing School of Business and Management (now merged into University of West London) and is a Fellow of the United Kingdom’s Chartered Institute of Management Accountants.

Paul Cleveland

Mr. Cleveland has served as a member of our board of directors since August 2015 and as Chairman of our board since November 2018. Mr. Cleveland served as our Interim President and Chief Executive Officer from March 2018 to June 2018. Mr. Cleveland is the Chairman of the Board of Adverum Biotechnologies, Inc. Previously, he was the President and Chief Executive Officer of Adverum. Before that, he was President and Chief Executive Officer of Celladon Corporation, and prior to that, was Celladon’s President and Chief Financial Officer. Prior to Celladon, he served as Executive Vice President, Corporate Strategy and Chief Financial Officer at Aragon Pharmaceuticals before its acquisition by Johnson & Johnson. Prior to Aragon, he was General Partner and Chief Operating Office at Mohr Davidow Ventures and Executive Vice President, Corporate Development and Chief Financial Officer for Affymax. He previously was a Managing Director at J.P. Morgan Chase and Co. and a predecessor firm, Hambrecht & Quist, and a corporate lawyer at Cooley LLP, Sidley Austin LLP, and Davis Polk & Wardwell LLP. Mr. Cleveland also served as a member of the board of directors and as Chairman of the Audit Committee of Sangamo Biosciences, Inc. from 2008 to 2016. Mr. Cleveland holds a bachelor’s degree from Washington University in St. Louis and a J.D. from Northwestern University School of Law.

Jeremy Green

Mr. Green has served as a member of our Board of Directors since April 2018. Since 2007, Mr. Green has served as the Founder and Portfolio Manager of Redmile Group, LLC, a San Francisco based investment firm that focuses on the healthcare sector. Prior to founding Redmile, Mr. Green served as Co-Founder and Director of Research at Steeple Capital L.P., and as an analyst at Andor Capital Management, L.L.C. Prior to that, Jeremy served as a Managing Director at Citigroup Inc. and Head of the European Healthcare Research Team covering medical technology, biotech and healthcare services. Mr. Green holds a B.A. in Natural Science – Biological Sciences and an M.A. from the University of Oxford.

A. Bruce Montgomery, M.D.

Dr. Montgomery has served as a member of our board of directors since October 2010. Dr. Montgomery is the Chief Executive Officer of Avalyn Pharma. In 2001, he founded Corus Pharma and served as its Chief Executive Officer from 2001 through its acquisition in 2006 by Gilead Sciences. He continued on at Gilead post-acquisition until 2010 and served as Senior Vice President and Head of Respiratory Therapeutics, where he successfully led the approval of Cayston (aztreonam) as a treatment for cystic fibrosis patients. From 2010 to 2016, he was the Chief Executive Officer of Cardeas Pharma. From 1993 to 2000, Dr. Montgomery held positions within the research and development group of PathoGenesis Corporation, a biotechnology company. From 1989 to 1993, Dr. Montgomery worked at Genentech, Inc., a biotechnology company. Dr. Montgomery currently serves on the board of directors of Xencor, Imc., and he previously served on the board of directors of ZymoGenetics, Inc. from 2009 to 2010. Dr. Montgomery holds an M.D. and a B.S. in Chemistry from the University of Washington.

Heather Preston, M.D.

Dr. Preston has served as a member of our board of directors since December 2007. Since 2005, Dr. Preston has served as a Managing Director at TPG BioTech, a biotechnology venture capital firm. Prior to joining TPG BioTech, Dr. Preston served for two years as a medical device and biotechnology venture capital investor at JP Morgan Partners, LLC, a private equity firm. Prior to that, she was an entrepreneur-in-residence at New Enterprise Associates, a venture capital firm. From 1997 to 2002, Dr. Preston served as a leader of the pharmaceutical and medical products consulting practice at McKinsey & Co. in New York. Dr. Preston currently serves as a director on numerous private company boards of directors. Dr. Preston holds an M.D. from the University of Oxford and a B.S. in biochemistry from the University of London.

Clay B. Siegall, Ph.D.

Dr. Siegall has served as a member of our board of directors since September 2005. In 1998, Dr. Siegall co-founded Seattle Genetics, Inc. and currently serves as its President, Chief Executive Officer and Chairman of the Board of Directors. From 1991 to 1997, Dr. Siegall was with the Bristol-Myers Squibb Pharmaceutical Research Institute and the National Cancer Institute, National Institutes of Health from 1988 to 1991. In addition to Seattle Genetics, Dr. Siegall currently serves on the board of directors of Ultragenyx Pharmaceutical Inc. Dr. Siegall holds a Ph.D. in Genetics from George Washington University and a B.S. in Zoology from the University of Maryland.

Wendy Yarno

Ms. Yarno has served as a member of our board of directors since April 2017. She has more than 30 years of experience in the pharmaceutical industry as a public company director and product commercialization team leader, including 26 years with Merck & Co. Inc. While at Merck, Ms. Yarno focused on drug development, regulatory strategy, market development, global product strategy, and product lifecycle management. Most recently until her retirement in 2008, she was chief marketing officer with oversight of a global team that handled pre- and post-launch product commercialization activities for more than 20 therapeutic areas. She has served on the boards of emerging biopharmaceuticals and medical technology companies, including St. Jude Medical Inc., Medivation Inc., Durata Therapeutics Inc., ADial Pharmaceuticals LLC., and PluroGen Therapeutics LLC. She currently serves on the boards of Aratana Therapeutics Inc. and MyoKardia, Inc.